The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy.

By Christy Santhosh June 12 (Reuters) - Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca failed to meet the ...

Although cancer treatments are improving fast, prevention has so far been mostly about promoting a healthy lifestyle. But ...

Lung cancer may not be the most common cancer diagnosis in the United States—that would be prostate cancer for men and breast ...

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the ...

The trial was conducted by PharmaMar to evaluate the drug as a second-line treatment in patients with relapsed metastatic small cell lung cancer where first-line treatment wasn't ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed. | ...

When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment ...

An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small ...

The technology is being rolled out at the Royal Surrey NHS Foundation Trust.

Barry Manilow returned to the stage in Glasgow after a six-month hiatus following a lung cancer diagnosis, underscoring his ...

Lung cancer causes abnormal cells to grow in your lungs. You are at higher risk for lung cancer if you are a current smoker or have smoked regularly in the past. But anyone can get lung cancer. In ...